

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL


OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity	
CIK (Filer ID Number) Previous Name(s) None	Entity Type
0001498382 Berry Only Inc.	© Corporation
Name of Issuer	C Limited Partnership
DelMar Pharmaceuticals, Inc.	C Limited Liability Company
Jurisdiction of Incorporation/Organization	C General Partnership
NEVADA	C Business Trust
Year of Incorporation/Organization	C Other
Over Five Years Ago	
Within Last Five Years (Specify Year)	
C Vet to Be Formed	

2. Principal Place of Business and Contact Information			
Name of Issuer			
DelMar Pharmaceuticals, Inc.			
Street Address 1	Stre	eet Address 2	
SUITE 720-999 WEST BROADV	VAY		
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
VANCOUVER	BRITISH COLUMBIA, CANADA	V5Z 1K5	(604) 629-5989



Relationship:	Executive Officer	Director	Promoter
Clarification of Respo	nse (if Necessary)		
Officer			
Last Name	First Name		Middle Name
Praill	Scott		
Street Address 1		Street Address 2	
Suite 720-999 West	t Broadway		
City	State/Province/	/Country	ZIP/Postal Code
Vancouver		DLUMBIA, CANADA	V5Z 1K5
vaneouver		DECIMENT, CHINADA	132 IK3
Relationship:	Executive Officer	Director	Promoter
Clarification of Respo	nse (if Necessary)		
Officer			
Last Name	First Name		Middle Name
Garner	William		
Street Address 1		Street Address 2	
	t Duoodyyay	Street Address 2	
Suite 720-999 West			
City	State/Province/		ZIP/Postal Code
Vancouver	BRITISH CC	DLUMBIA, CANADA	V5Z 1K5
Relationshins	Executive Officer	□ Director	Promoter
Relationship:	Executive Officer	Director	Promoter
Clarification of Respo	nse (if Necessary)		
			_
Last Name	First Name		Middle Name
Bell	John		K.
Street Address 1		Street Address 2	
Suite 720-999 West	t Broadway		
City	State/Province/	Country (Country	ZIP/Postal Code
Vancouver	BRITISH CO	DLUMBIA, CANADA	V5Z 1K5
Relationship:	Executive Officer	□ Director	Promoter
Clarification of Respo	nse (if Necessary)		
or respo	(
L			

4. Industry Group

C Agriculture	Health Care C Retailing	
Banking & Financial Services	C Biotechnology	
C Commercial Banking	C Hespitale & Dhysicians	
C Insurance	Pharmaceuticals	
C Investing	C Other Health Care	
C Investment Banking	C Telecommunications	
C Pooled Investment Fund	C Other Technology	
Other Banking & Financial	Travel	
C Services	Manufacturing C Airlines & Airports	
C Business Services	Real Estate C Lodging & Conventions	
Energy C Coal Mining	C Commercial C Tourism & Travel Services	
C Electric Utilities	C Construction C Other Travel C REITS & Finance	
C Energy Conservation	C Residential C Other	
C Environmental Services	Other Real Estate	
C Oil & Gas		
C Other Energy		
5. Issuer Size		
	Accurate Net Accet Value Dance	
Revenue Range No Revenues	Aggregate Net Asset Value Range No Aggregate Net Asset Value	
C \$1 - \$1,000,000	C \$1 - \$5,000,000	
C \$1,000,001 - \$5,000,000	C \$5,000,001 - \$25,000,000	
© \$5,000,001 - \$25,000,000	C \$25,000,001 - \$50,000,000	
© \$25,000,001 - \$100,000,000	C \$50,000,001 - \$100,000,000	
Over \$100,000,000	Over \$100,000,000	
C Decline to Disclose	C Decline to Disclose	
C Not Applicable	C Not Applicable	
Not Applicable	140t Applicable	
6. Federal Exemption(s) apply)	and Exclusion(s) Claimed (select all that	
Rule 504(b)(1) (not (i), (ii)	Rule 505	
or (iii))	Table 500	
	Rule 506(b)	
Rule 504 (b)(1)(ii)	Rule 506(c)	
	Rule 506(c) Securities Act Section 4(a)(5)	
Rule 504 (b)(1)(ii)		
Rule 504 (b)(1)(ii)	Securities Act Section 4(a)(5)	
Rule 504 (b)(1)(ii)	Securities Act Section 4(a)(5)	
Rule 504 (b)(1)(ii)	Securities Act Section 4(a)(5)	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing	Securities Act Section 4(a)(5) Investment Company Act Section 3(c)	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale	Securities Act Section 4(a)(5)	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing	Securities Act Section 4(a)(5) Investment Company Act Section 3(c)	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale	Securities Act Section 4(a)(5) Investment Company Act Section 3(c)	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale	Securities Act Section 4(a)(5) Investment Company Act Section 3(c)	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale Amendment	Securities Act Section 4(a)(5) Investment Company Act Section 3(c)	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale Amendment 8. Duration of Offering	Securities Act Section 4(a)(5) Investment Company Act Section 3(c) 2013-01-25 First Sale Yet to Occur	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale Amendment	Securities Act Section 4(a)(5) Investment Company Act Section 3(c) 2013-01-25 First Sale Yet to Occur	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale Amendment 8. Duration of Offering	Securities Act Section 4(a)(5) Investment Company Act Section 3(c) 2013-01-25 First Sale Yet to Occur	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale Amendment 8. Duration of Offering Does the Issuer intend this offering to last	Investment Company Act Section 3(c) 2013-01-25 First Sale Yet to Occur The more than one year? Yes No	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale Amendment 8. Duration of Offering Does the Issuer intend this offering to last 9. Type(s) of Securities (Investment Company Act Section 3(c) 2013-01-25 First Sale Yet to Occur The more than one year? Yes No Offered (select all that apply)	
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) 7. Type of Filing New Notice Date of First Sale Amendment 8. Duration of Offering Does the Issuer intend this offering to last 9. Type(s) of Securities (Investment Company Act Section 3(c) 2013-01-25 First Sale Yet to Occur The more than one year? Yes No Offered (select all that apply)	

Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other Right to Acquire
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Clarification of Response (if Necessary)
11. Minimum Investment
Minimum investment accepted from any outside sinvestor USD
12. Sales Compensation
Recipient CRD Number None
Charles Vista, LLC 132650
(Associated) Broker or Dealer None (Associated) Broker or Dealer CRD Number None
Street Address 1 Street Address 2
201 Edward Curry Avenue Suite 103
City State/Province/Country ZIP/Postal Code
Staten Island NEW YORK 10314
State(s) of Solicitation

NEW YORK	
NEVADA	
CALIFORNIA	
MICHIGAN	
ОНІО	
FLORIDA	
MARYLAND	
MASSACHUSETTS	
ILLINOIS	
UTAH	
INDIANA	
CONNECTICUT	
WEST VIRGINIA	
MINNESOTA	
WISCONSIN	
ARIZONA	
KANSAS	
MONTANA	
LOUISIANA	
WASHINGTON	
NEW JERSEY	
ALASKA	
ALABAMA	
TEXAS	
COLORADO	
NORTH CAROLINA	
13. Offering and Sales Amounts	
Total Offering Amount \$ 10500000 US	D
Total Amount Sold \$ 10500000 US	D
Total Remaining to be \$\int \begin{aligned} \b	D 🗖 Indefinite
Clarification of Response (if Necessary)	
1.4 Investors	
14. Investors	
Select if securities in the offering have been or made on the do not qualify as accredited investors,	y be sold to persons who
Number of such non-accredited investors who alr	eady have invested in the
offering	
Regardless of whether securities in the offering he to persons who do not qualify as accredited invest	tors, enter the total
number of investors who already have invested in	the offering:

15. Sales Commissions & Finders' Fees Expenses

10% Placement Agent Fee and 3% non-accountable expense.			
Clarification of Response (if Necessar	ry)		
Finders' Fees	\$ 0	USD	Estimate
Sales Commissions	\$ 1365000	USD 🔽	Estimate

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

Clarification of Response (if Necessary)

Mr. Bacha, CEO, is under contract with the corporation and receives remuneration of \$12,000 per month for services.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
DelMar Pharmaceuticals, Inc.	/s/ Jeffrey Bacha	Jeffrey Bacha	Chief Executive Officer	2013-03-07